Published by
AFP
AFP
New York (AFP) – American drugmaker Pfizer is close to a deal to purchase Global Blood Therapeutics, which manufactures a recently approved drug against sickle-cell anemia, for $5 billion, the Wall Street Journal has reported. Pfizer, one of the top makers of Covid-19 vaccines, hopes to conclude talks with GBT within days, the newspaper said Friday, citing people close to the negotiations. But it said other takeover candidates remain in the running. GBT’s sickle-cell treatment, marketed as Oxbryta, was authorized for those over 12 years old in 2019 but gained federal approval in December for …
Share this Story
